Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 16, Pages 3948
Publisher
MDPI AG
Online
2021-08-05
DOI
10.3390/cancers13163948
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
- (2020) Wenyan Zhong et al. BMC GENOMICS
- In transit melanoma and imiquimod: A case of disease progression
- (2020) Emi Dika et al. Dermatologic Therapy
- Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
- (2020) Chenglong Sun et al. OncoTargets and Therapy
- Increased both PD–L1 and PD–L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis
- (2020) Hidetaka Yasuoka et al. Scientific Reports
- A systematic review and meta-analysis of locoregional treatments for in-transit melanoma
- (2019) Tavis Read et al. JOURNAL OF SURGICAL ONCOLOGY
- Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
- (2019) Mariya Rozenblit et al. Scientific Reports
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma
- (2019) Emma H. A. Stahlie et al. JOURNAL OF SURGICAL ONCOLOGY
- The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
- (2019) Antje Tunger et al. Journal of Clinical Medicine
- Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
- (2019) Scott J Antonia et al. LANCET ONCOLOGY
- Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma
- (2019) Rebecca L Read et al. Expert Review of Clinical Pharmacology
- The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
- (2019) Zuzanna Urban-Wojciuk et al. Frontiers in Immunology
- IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway
- (2019) Hongning Cai et al. BIOMEDICINE & PHARMACOTHERAPY
- PD-1 Expression during Acute Infection Is Repressed through an LSD1–Blimp-1 Axis
- (2019) Alexander P. R. Bally et al. JOURNAL OF IMMUNOLOGY
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
- (2018) Deng Pan et al. SCIENCE
- Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
- (2018) Flávia Castro et al. Frontiers in Immunology
- PD-1 immunobiology in systemic lupus erythematosus
- (2018) Colleen S. Curran et al. JOURNAL OF AUTOIMMUNITY
- High FcγR Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy
- (2018) Hreinn Benonisson et al. JOURNAL OF IMMUNOLOGY
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Investigating the utility of human melanoma cell lines as tumour models
- (2017) Krista Marie Vincent et al. Oncotarget
- Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
- (2017) Lupe G. Salazar et al. JAMA Oncology
- CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling
- (2016) Nicla Porciello et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Imiquimod in dermatology: an overview
- (2016) Edith Hanna et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo
- (2016) Jing Wu et al. Oncotarget
- Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery
- (2016) Suzanne I.S. Mosely et al. Cancer Immunology Research
- Identification of an Immunogenic Subset of Metastatic Uveal Melanoma
- (2015) L. D. Rothermel et al. CLINICAL CANCER RESEARCH
- Type I IFN Contributes to the Phenotype ofUnc93b1D34A/D34AMice by Regulating TLR7 Expression in B Cells and Dendritic Cells
- (2015) Ryutaro Fukui et al. JOURNAL OF IMMUNOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- The TLR7 agonist induces tumor regression both by promoting CD4+T cells proliferation and by reversing T regulatory cell-mediated suppression via dendritic cells
- (2015) Chenchen Wang et al. Oncotarget
- The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options
- (2015) Emmanuel Gabriel et al. Cancers
- Combinatorial Immunotherapy of Polyinosinic–Polycytidylic Acid and Blockade of Programmed Death-Ligand 1 Induce Effective CD8 T-cell Responses against Established Tumors
- (2014) Toshihiro Nagato et al. CLINICAL CANCER RESEARCH
- The Common -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
- (2014) A. L. Kinter et al. JOURNAL OF IMMUNOLOGY
- Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation
- (2014) Manisha Singh et al. JOURNAL OF IMMUNOLOGY
- Imiquimod Inhibits Melanoma Development by Promoting pDC Cytotoxic Functions and Impeding Tumor Vascularization
- (2014) Caroline Aspord et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy of Imiquimod-Based Transcutaneous Immunization Using a Nano-Dispersed Emulsion Gel Formulation
- (2014) Pamela Stein et al. PLoS One
- Imiquimod attenuates the growth of UVB-induced SCC in mice through Th1/Th17 cells
- (2012) Maki Yokogawa et al. MOLECULAR CARCINOGENESIS
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Inhibition of established subcutaneous murine tumour growth with topical Melaleuca alternifolia (tea tree) oil
- (2010) Sara J. Greay et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice
- (2010) Fang Ma et al. Cellular & Molecular Immunology
- The roles of antigen-specificity, responsiveness to transforming growth factor-β and antigen-presenting cell subsets in tumour-induced expansion of regulatory T cells
- (2010) David Coe et al. IMMUNOLOGY
- Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG
- (2010) Jasper G. van den Boorn et al. PLoS One
- Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands
- (2009) Angela Meier et al. AIDS
- Molecular Mechanisms of IFN-γ to Up-Regulate MHC Class I Antigen Processing and Presentation
- (2009) Fang Zhou INTERNATIONAL REVIEWS OF IMMUNOLOGY
- Progress of multiple cutaneous and subcutaneous melanoma metastases of the face during imiquimod treatment
- (2009) Lutz Kowalzick et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Imiquimod Enhances IFN-γ Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin
- (2009) Susan J. Huang et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- TLR7 and TLR8 as targets in cancer therapy
- (2008) M P Schön et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started